A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

British Journal of Cancer

Volumn 110, Issue 3, 2014, Pages 602-608

  Chen, H ^a   Modiano, M R ^b   Neal, J W ^c   Brahmer, J R ^d   Rigas, J R ^e   Jotte, R M ^f   Leighl, N B ^g   Riess, J W ^c   Kuo, C J ^c   Liu, L ^h   Gao, B ^h   Dicioccio, A T ^h   Adjei, A A ^a   Wakelee, H A ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Arizona Clinical Research Center and Arizona Oncology   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f ROCKY MOUNTAIN CANCER CENTERS   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

anti angiogenesis; non small cell lung cancer; reversible posterior leukoencephalopathy syndrome; ziv aflibercept

Indexed keywords

AFLIBERCEPT; CISPLATIN; CREATININE; PEMETREXED;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HICCUP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INSOMNIA; LIMB PAIN; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RHINORRHEA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84893745037     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.735     Document Type: Article

References (38)

1. Allegra CJ, Tabernero J, Rougier P, Scagliotti GV, Philip PA, Lakomy R, Ramlau R, Assadourian S, Chevalier S, Van Cutsem E (2012) Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled phase III trials with IV aflibercept (Afl). J Clin Oncol 30(Suppl 4): abstract 561.
2. Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 29: 1036-1042.
3. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28: 949-954.
4. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, DeAngelis LM, Yung WKA, Chen A, Prados MD, Wen PY (2011) Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium Study. J Clin Oncol 29: 2689-2695.
5. Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, Razak ARA, Colevas AD, Shepherd FA, Leighl NB, Neal JW, Thibault A, Liu L, Lisano J, Gao B, Lawson EB, Wakelee HA (2012) A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Br J Cancer 107: 604-611.
6. Dowlati A (2010) Hunting and trapping the vascular endothelial growth factor. J Clin Oncol 28: 185-187.
7. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25.
8. Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763.
9. Freyer G, Isambert N, You B, Zanetta S, Falandry C, Favier L, Trillet-Lenoir V, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Fumoleau P (2012) Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours. Br J Cancer 107: 598-603.
10. Gadgeel SM (2012) Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer 13: 96-106.
11. Gaya A, Tse V (2012) A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 38: 484-493.
12. Glusker P, Recht L, Lane B (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354: 980-982.
13. Hinchey J, ChavesC, Appignani B, Breen J, Pao L,Wang A, PessinMS, Lamy C, Mas J-L, Caplan LR (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334: 494-500.
14. Isambert N, Freyer G, Zanetta S, You B, Fumoleau P, Falandry C, Favier L, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Trillet-Lenoir V (2012) Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 18: 1743-1750.
15. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G (1998) Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 19: 415-417.
16. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7: 987-989.
17. Korpanty G, Smyth E, Sullivan LA, Brekken RA, Carney DN (2010) Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med 235: 3-9.
18. Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G, Lee WMF (2010) Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 10: 1326-1333.
19. Lee VH, Wijdicks EFM, Manno EM, Rabinstein AA (2008) Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 65: 205-210.
20. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS (2010) A multicenter, phase 2 study of vascular endothelial growth factor trap (aflibercept) in platinumand erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 5: 1054-1059.
21. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP (2010) Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28: 207-214.
22. Marinella MA, Markert RJ (2009) Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J 39: 826-834.
23. National Cancer Institute (2006) Common Terminology Criteria for Adverse Events, Version 3.0. Available from http://ctep.cancer.gov (accessed 28 August 2013).
24. Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC (2009a) Treatment rationale and study design for the PointBreak study: A randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/ bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 10: 252-256.
25. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD (2009b) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27: 3284-3289.
26. Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller VA, Thatcher N, Scagliotti GV (2012) Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 30: 3640-3647.
27. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27: 1227-1234.
28. Riess JW, Logan AC, Krupitskaya Y, Padda S, Clement-Duchene C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA (2012) Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Cancer Invest 30: 231-235.
29. Sandler AB, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
30. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
31. Schiller JH, Harrington DP, Belani CP, Langer CJ, Sandler AB, Krook JE, Zhu J, Johnson DH. the Eastern Cooperative Oncology Group. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
32. Sher A, Wu S (2011) Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis. Acta Oncol 50: 997-1005.
33. Sitohy B, Nagy JA, Jaminet S-CS, Dvorak HF (2011) Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Cancer Res 71: 7021-7028.
34. Tam BYY, Wei K, Rudge JS, Hoffman J, Holash J, Park S, Yuan J, Hefner C, Chartier C, Lee J-S, Jiang S, Nayak NR, Kuypers FA, Ma L, Sundram U, Wu G, Garcia JA, Schrier SL, Maher JJ, Johnson RS, Yancopoulos GD, Mulligan RC, Kuo CJ (2006) VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12: 793-800.
35. Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, Sabbatini P, Mendelson D, Schwartz L, Gettinger S, Psyrri A, Cedarbaum JM, Spriggs DR (2010) Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 16: 358-366.
36. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst 92: 205-216.
37. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499-3506.
38. Vaughn C, Zhang L, Schiff D (2008) Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 10: 86-91.